Production issues could put a damper on Novo Nordisk's 2022
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13574743.ece/ALTERNATES/schema-16_9/doc7ix2g3o3ymbmfinpmk6.jpg)
Analysts and investors are concerned about Novo Nordisk’s current production problems with obesity drug Wegovy, which have arisen due to issues at the Danish pharmaceutical company’s contract manufacturer, Catalent, reports Danish business media Børsen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Catalent behind Novo Nordisk's supply issues, says media
For subscribers